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Abstract: Background: Poor pharmacokinetic profiles and resistance are the main two drawbacks
from which currently used antiviral agents suffer, thus make them excellent targets for research,
especially in the presence of viral pandemics such as HIV and hepatitis C. Methods: The strategies
employed in the studies covered in this review were sorted by the type of drug synthesized into ester
prodrugs, targeted delivery prodrugs, macromolecular prodrugs, other nucleoside conjugates, and
non-nucleoside drugs. Results: Utilizing the ester prodrug approach a novel isopropyl ester prodrug
was found to be potent HIV integrase inhibitor. Further, employing the targeted delivery prodrug
zanamivir and valine ester prodrug was made and shown a sole delivery of zanamivir. Additionally,
VivaGel, a dendrimer macromolecular prodrug, was found to be very efficient and is now undergoing
clinical trials. Conclusions: Of all the strategies employed (ester, targeted delivery, macromolecular,
protides and nucleoside analogues, and non-nucleoside analogues prodrugs), the most promising are
nucleoside analogues and macromolecular prodrugs. The macromolecular prodrug VivaGel works
by two mechanisms: envelope mediated and receptor mediated disruption. Nucleotide analogues
have witnessed productive era in the recent past few years. The era of non-interferon based treatment
of hepatitis (through direct inhibitors of NS5A) has dawned.
Keywords: antiviral; macromolecules; prodrug; nucleoside; non-nucleoside; protide; targeted delivery
1. Introduction
Despite the high efficiency of the human immune system, viruses are ubiquitous and versatile
organisms with the potential to cause serious illnesses that require aggressive pharmacological
intervention, yet existing medicines are by and large inefficient at combatting viruses, making them a
target for aggressive exploration to accelerate the development of new antiviral agents.
The WHO estimates that there are a total of 36.7 million people living with HIV [1] and 257 million
people living with hepatitis B [2]. These two main infections, as well as pandemics, have urged the
scientific community to explore and develop novel and more potent antiviral agents.
There are two main approaches to antiviral prodrug design: the traditional or classical approach
and the modern one. While the traditional approach aims to alter the physiochemical properties, such
as lipophilicity by covalently modifying the drug either to increase its solubility by attaching it to
hydrophilic functionalities [3] or to increase its passive permeability by attaching lipophilic moieties [4],
the modern approach targets molecular and cellular entities such as membrane influx/efflux
transporters and cellular protein expression and distribution [5].
In light of previously published articles which have reviewed antiviral drug strategies and novel
antiviral agents [6–12], this review aims to explore strategies employed by researchers in the production
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of novel antiviral drugs and prodrugs published during the recent five years. The strategies were
sorted by the type of drug synthesized into ester prodrugs, targeted delivery prodrugs, macromolecular
prodrugs, other nucleoside conjugates, non-nucleoside drugs, and nanoparticles.
2. Ester Prodrugs
One of the more common and widely applicable prodrug design strategies is using an ester
linkage to pair an existing active drug with an organic moiety. On the other side of the ester linkage,
the chosen moiety has the potential to be another active agent, a carrier to exploit transfer mechanisms,
or a lipophilic entity to increase permeability. Whichever the chosen moiety is, an ester linkage
provides a readily cleavable site susceptible to both chemical and enzyme mediated cleavage.
Dalpiaz et al. [13] have attempted to use ursodeoxycholic acid (UDCA, 1 in Figure 1) to increase the
permeability of azidothymidine (AZT, 2 in Figure 1) into the sanctuaries of HIV in the central nervous
system (CNS) and macrophages. The resulting UDCA-AZT prodrug (3 in Figure 1) (all prodrugs
illustrated in the figures depicted throughout the review are highlighted in blue), which results from
a 5′-ester conjugation of AZT with the bile acid ursodeoxycholic acid (UDCA), was found to be
hydrolysed at slow rates in human plasma and whole blood (half-life: 7.5 h and 3.7 h, respectively)
thus controlling AZT release. Moreover, it proved to be able to bypass active efflux CNS systems and
to deliver up to twenty times more of AZT to the site of action in macrophages.
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Figure 1. Chemical structures of ursodeoxycholic acid (UDCA) (1), azidothymidine (AZT) (2), and the 
prodrug (AZT-UDCA) (3). 
HIV-1 integrase, an enzyme required for HIV replication, is another target for anti-HIV agents. 
While raltegravir (4 in Figure 2) is the only compound discovered to work on the HIV integrase 
enzyme, Seo et al. [14] have synthesized a lead compound, (4-(1.5-dibenzyl-1,2-dihydro-2-oxo-
pyridin-3-yl)-2-hydroxy-4-oxobut-2-enoic acid), which was used in the design of potent HIV 
integrase inhibitors with favourable pharmacokinetic and pharmacodynamic profiles (in vitro half-
life of >3 h post incubation in liver microsomes). The original lead compound suffered from poor 
cellular permeability which was improved by the synthesis of a novel isopropyl ester prodrug of a 
similar derivative (5 in Figure 2). 
Figure 1. Che ical structures of ursodeoxycholic acid (UDCA) (1), azidothy idine (AZT) (2), and the
prodrug ( ZT-UDCA) (3).
HIV-1 integrase, an enzyme required for HIV replication, is another target for anti-HIV
agents. While raltegravir (4 in Figure 2) is the only compound discovered to work
on the HIV integrase enzyme, Seo et al. [14] have synthesized a lead compound,
(4-(1.5-dibenzyl-1,2-dihydro-2-oxo-pyridin-3-yl)-2-hydroxy-4-oxobut-2-enoic acid), which was used in
the design of potent HIV integrase inhibitors with favourable pharmacokinetic and pharmacodynamic
profiles (in vitro half-life of >3 h post incubation in liver microsomes). The original lead compound
suffered from poor cellular permeability which was improved by the synthesis of a novel isopropyl
ester prodrug of a similar derivative (5 in Figure 2).
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In another study by Gupta et al. [24] a series of guanidine oseltamivir carboxylate (GOC) 
prodrugs has been synthesized to overcome the bioavailability drawbacks (high polarity) of the 
parent drug, oseltamivir (8 in Figure 4). The prodrugs were also designed with PEPT1 targeting in 
mind. The prodrug with the ideal results was found to be GOC-L-Val (9 in Figure 4); the valine ester 
of GOC, which showed enhanced absorption in mice when compared to the original drug. 
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3. Targeted Transporters Approach
Due to the main major drawbacks from which antivirals suffer, targeting intestinal transporters
has great potential to facilitate their absorption. Hence, research exploiting this strategy has gained
pace. Transporters targeted include organic anion transporters (OAT) [15], organic cation transporters
(OCT) [16], sodium dependent bile acid transporters (ASBT) [17], sodium-dependent glucose
transporters (SGLT) [18], monocarboxylate transporters (MCT) [19], and oligopeptide transporters
(PEPT1) [20,21].
Zanamivir’s (6 in Figure 3) polar and zwitterion forms cause the drug to have poor bioavailability
and render its use as a drug of choice for prodrug formulation [22]. Gupta et al. [23] thus aimed to target
the intestinal transport pathway through PEPT1 by formulating a zanamivir and valine ester prodrug
(7 in Figure 3). The resulting prodrug exhibited substantially higher permeability (9 fold higher than
zanamivir) and complete hydrolysis in mucosal cells, leading to the sole delivery of zanamivir.
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In another study by Gupta et al. [24] a series of guanidine oseltamivir carboxylate (GOC)
prodrugs has been synthesized to overcome the bioavailability drawbacks (high polarity) of the
parent drug, oseltamivir (8 in Figure 4). The prodrugs were also designed with PEPT1 targeting in
mind. The prodrug with the ideal results was found to be GOC-L-Val (9 in Figure 4); the valine ester of
GOC, which showed enhanced absorption in mice when compared to the original drug.
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HIV drugs such as abacavir (10 in Figure 5) have been shown to be good P-gp substrates when tested 
via in vitro experiments [25]. Namanja et al. [26] hence designed abacavir dimers to act as P-gp 
substrates. The idea behind the dimer entity is that it would act as a P-gp inhibitor and allow for high 
concentrations of the drug to entering the CNS while the intracellular environment would induce the 
cleavage of the dimer into the therapeutically active abacavir monomers [27]. The prodrug designed 
(11 in Figure 5) was comprised of two abacavir molecules linked via a ‘traceless tether’—a molecule 
which would be removed completely from the monomers once inside the cells. This tether was a 
simple disulfide linkage linked via ester linkages at both ends to the abacavir monomers. The team 
showed that the dimer was a potent P-gp inhibitor and completely dissociates into monomers 
intracellularly. 
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4. Macromolecular Prodrugs 
As a result of the high molecular weights of macromolecules (polymers) and their tunable 
potential, their application in the biomedical field has received considerable attention for the use as 
a tool for optimizing the pharmacokinetics profiles of conjugated drugs or proteins [28,29].  
For instance, a significant number of studies have reported a vast value of the use of macromolecular-
based prodrugs for improving the therapeutic activity of anticancer drugs [30–33]. 
As for antiviral drugs, the interest behind the applications of macromolecules is not solely 
limited to their potential in improving the delivery and pharmacokinetics of antiviral agents, but also 
due to the non-specific polymer-charge effect which is exhibited by macromolecules on viruses. 
Hence, leading to the inhibition of virus entry into mammalian cells [29,34]. Upon further 
Figure 4. Chemical structures of oseltamivir (8) and its GOC-L-Val prodrug 9.
P-gp is an integral transport protein expressed extensively in intestinal epithelium as well as
the blood brain barrier and is responsible for limiting the penetration of many drugs into the CNS.
Anti-HIV drugs such as abacavir (10 in Figure 5) have been shown to be good P-gp substrates when
tested via in vitro experiments [25]. Namanja et al. [26] hence designed abacavir dimers to act as P-gp
substrates. The idea behind the dimer entity is that it would act as a P-gp inhibitor and allow for high
concentrations of the drug to entering the CNS while the intracellular environment would induce the
cleavage of the dimer into the therapeutically active abacavir monomers [27]. The prodrug designed
(11 in Figure 5) was comprised of two abacavir molecules linked via a ‘traceless tether’—a molecule
which would be removed completely from the monomers once inside the cells. This tether was a simple
disulfide linkage linked via ester linkages at both ends to the abacavir monomers. The team showed
that the dimer was a potent P-gp inhibitor and completely dissociates into monomers intracellularly.
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to the non-specific polymer-charge effect which is exhibited by macromolecules on viruses. Hence,
leading to the inhibition of virus entry into mammalian cells [29,34]. Upon further investigation of the
polymer charge effect, it became clear that poly-anionic macromolecules inhibit viruses extracellularly
by denying them cell entry in the first place [35–38], while poly-cationic macromolecules, on the
other hand, are complexed with the genetic material of the virus [39]. Moreover, macromolecules
play an essential role in controlling the release, distribution, and nonselective accumulation of the
conjugated drugs [40–45].
Macromolecule prodrugs strategy can be subdivided into natural, semi-synthetic, and synthetic
macromolecule conjugates depending on the nature of the linkage between the parent drug
and conjugate.
Previous research has been directed towards using naturally occurring macromolecules in the
synthesis of antiviral prodrugs. One example is haemoglobin, which was used in an effort to
improve the safety profile of ribavirin [46,47]. Furthermore, chondroitin sulphate, a sulphated natural
glycosaminoglycan, was shown to have inhibitory action on dengue viruses through its interaction
with envelop E protein resulting in diminished virus entry to cells [48].
However, natural macromolecules suffer from many drawbacks such as batch-to-batch variations
and immunogenic reactions. Hence, research has been more directed towards the use of semi and fully
synthetic polymers.
In a study by Liang et al. [49] chitosan (COS), a semi-synthetic polysaccharide formed from
alkaline deacetylation of chitin, is used as a macromolecular carrier for AZT. In an effort to control the
distribution of the drug and limit its rapid blood elimination, the linker of choice was a biodegradable
succinic (suc) ester between AZT and the macromolecule which allows for sustained release of the drug
(see 12 in Figure 6). The research team was able to confirm sustained release of the orally administered
drug in mice as well as selective renal targeting via fluorescence imaging.
Molecules 2017, 22, 1736 5 of 17 
 
investigation of th  polymer charge effect, it became lear that poly-anionic mac omolecules inhibit 
virus s extracellular y by de ying them cell entry in t e first place [35–38], while poly-cationic 
macromolecules, on the other and, are co pl xed wi  the genetic mat rial of the virus [39]. 
Moreover, macromolecules play an ssential role in c trolling th  release, distribution, and 
n selective accumulation of the conjugated drugs [40–45]. 
           
l  conjugates depending on the nature of the linkage b tw en the parent drug and 
conjugate. 
            
 of antiviral prodrugs. One example is haemoglobin, which was used in an effort to imp ove 
the saf ty profile of ribavi n [46,47]. Furthermo e, chondroitin sulphate, a sulphated  
i l c , s            
    lti  i  i i i  ir s tr  t  cells [48]. 
, natural macromolecules suffer from many drawbacks suc  as batch-to-batch 
variations and immunogenic rea tion . Hence, res arch has b en m re direct d towards the use of 
emi and ful  synthetic polymers. 
        it        
 t l ti  of chitin, is used as a macromolecular carrier for AZT. I  an effort to control 
the distribution of the drug and limit its rapid blood elimination, the linker of choice was a 
biodegradabl  succinic (suc) ester be ween AZT and the macromolecule which allows for sustained 
rel ase of the drug (se  12 in Figure 6). The r search team w s able to confirm sustaine  release of 
the orally administered drug in mice as w ll as selective renal targeting via fluorescence imaging. 
 
Figure 6. Chemical structure of the AZT-suc-COS prodrug 12. 
Also employing the succinic ester linkage, Neeraj et al. [50] have conjugated AZT to poly-2-
hydroxyethyl methacrylate (HPMA), a fully synthetic macromolecule, to obtain a macromolecular 
prodrug (13 in Figure 7) with the aim of improving the pharmacokinetic profile of AZT. In vitro 
studies performed by the team showed that the resulting prodrug managed to increase both the half-life 
(8 h for the prodrug vs. 1 h for AZT) and bioavailability of AZT (1470 ng h/mL vs. 645 ng h/mL). 
Zuwala et al. [51], have also utilized acrylate derivatives in synthesizing two polymers. The 
group synthesized conjugates with poly(methacrylic acid) (PMAA) and HPMA (14 and 15 in Figure 8, 
respectively), and claimed that the PMAA-AZT conjugate resulted in a longer duration of action 
when compared to the pristine drug. Furthermore, they reported that the conjugate exhibits its 
antiviral activity both extracellularly by adsorption and intracellularly on reverse transcription. 
However, the study was only able to visualize the internalization of the HPMA conjugate using 
fluorescence. 
Figure 6. Chemical structure of the AZT-suc-COS prodrug 12.
Also employing the succinic ester linkage, Neeraj et al. [50] have conjugated AZT
to poly-2-hydroxyethyl methacrylate (HPMA), a fully synthetic macromolecule, to obtain a
macromolecular prodrug (13 in Figure 7) with the aim of improving the pharmacokinetic profile
of AZT. In vitro studies performed by the team showed that the resulting prodrug managed to increase
both the half-life (8 h for the prodrug vs. 1 h for AZT) and bioavailability of AZT (1470 ng h/mL vs.
645 ng h/mL).
Zuwala et al. [51], have also utilized acrylate derivatives in synthesizing two polymers. The group
synthesized conjugates with poly(methacrylic acid) (PMAA) and HPMA (14 and 15 in Figure 8,
respectively), and claimed that the PMAA-AZT conjugate resulted in a longer duration of action when
compared to the pristine drug. Furthermore, they reported that the conjugate exhibits its antiviral
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activity both extracellularly by adsorption and intracellularly on reverse transcription. However, the
study was only able to visualize the internalization of the HPMA conjugate using fluorescence.Molecules 2017, 22, 1736 6 of 17 
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study by Tyssen et al. [55], ‘dendrimers’, macromolecules comprised of a core with extensive well 
defined branching were studied. The core of the macromolecules was lysine functionalized with 
seven different functional groups being naphthyl and sulfonic acid derivatives. Two main factors 
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Of a series of dendrimers synthesized, SPL7013 was the best potential candidate as it exhibited 
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transmission model. SPL7013, also known as VivaGel®, exhibits its antiviral activity through blocking 
HIV-1 entry to the cells by blocking R5 and X4 envelope mediated cell-to-cell fusion as well as 
inhibiting recombinant HIV-1 reverse transcriptase. The authors report that VivaGel®, one of the 
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Of a series of dendrimers synthesized, SPL7013 was the best potential candidate as it exhibited
broad-spectrum anti-HIV activity as well as long-lived protection against HSV-2 in mouse vaginal
transmission model. SPL7013, also known as VivaGel®, exhibits its antiviral activity through blocking
HIV-1 entry to the cells by blocking R5 and X4 envelope mediated cell-to-cell fusion as well as inhibiting
recombinant HIV-1 reverse transcriptase. The authors report that VivaGel®, one of the dendrimers
studied, was in clinical development. It is worth mentioning that VivaGel® is now undergoing
clinical trials [56].Molecules 2017, 22, 1736 7 of 17 
 
 
Figure 9. Chemical structures of RBV-AA (16) and RBV-NVP (17). 
5. ProTides and Nucleoside Analogues 
Nucleoside-based antiviral agents are synthetic agents whose structure is similar to the naturally 
occurring nucleosides of DNA and RNA [12]. They are considered as the most common antiviral 
agents with immuno-modulating activity. However, nucleoside analogues suffered from undesirable 
pharmacokinetic profiles and poor antiviral activity leading to biological toxicity and drug resistance. 
Once a nucleoside analogue is taken up by the cell, it is activated via three intracellular 
phosphorylation steps through viral and cellular kinases to nucleoside-triphosphate, with the first 
phosphorylation of nucleosides representing the rate-limiting step. 
In order to eliminate these drawbacks, previous work on formulating antiviral prodrugs which 
was focused on the synthesis and delivery of phosphorylated nucleoside analogues aiming to overcome 
the rate-limiting step. However, these analogues were faced by premature dephosphorylation and 
inefficient cellular uptake due to their charged nature leading to further research aimed towards 
improving them [57]. ProTides, a novel technology first employed by McGuigan [58], aims to mask 
the phosphoryl oxygen groups in order to mask their charge and improve cellular uptake. This strategy 
has proved successful in delivering drugs to the market such as sofosvubir and tenofovir alafenamide. 
INX-08189, also known as INX-189, is a potent hepatitis C (HCV) virus replication inhibitor 
prodrug prepared initially from a guanosine derivative (18 in Figure 10). The starting compound 
undergoes masking and modification of the ester and amino acid moieties, as well as 
phosphorylation, which allows the drug to become active intracellularly. Afterwards, the prodrug is 
prepared by masking the phosphoryl group. INX-08189 (19 in Figure 10) was found to be 500 times 
more potent than the parent nucleoside. Unfortunately, INX-08189 was discontinued in 2012 during 
phase II development due to its high cardiac toxicity [59–61]. 
Structurally similar to INX-08189, both PSI-353661 (20 in Figure 10) and PSI-7977 have proceeded 
to clinical evaluation with impressive early results. PSI-353661, a protide prodrug, was discovered by 
Chang et al. in 2011 [62] and showed superior anti-HCV potency vs. the original guanosine derivative 
in addition to good stability (half-life > 24 h). PSI-7977 would later be acquired by Gilead Sciences 
under GS-7977 and eventually marketed as Sovaldi®. 
Figure 9. Chemical structures of RBV-AA (16) and RBV-NVP (17).
5. ProTides and Nucleoside Analogues
Nucleoside-based antiviral agents are synthetic agents whose structure is similar to the naturally
occurring nucleosides of DNA and RNA [12]. They are considered as the most common antiviral
agents with immuno-modulating activity. However, nucleoside analogues suffered from undesirable
pharmacokinetic profiles and poor antiviral activity leading to biological toxicity and drug resistance.
Once a nucleoside analogue is taken up by the cell, it is activated via three intracellular phosphorylation
steps through viral and cellular kinases to nucleoside-triphosphate, with the first phosphorylation of
nucleosides representing the rate-limiting step.
In order to eliminate these drawbacks, previous work on formulating antiviral prodrugs which
was focused on the synthesis and delivery of phosphorylated nucleoside analogues aiming to overcome
the rate-limiting step. However, these analogues were faced by premature dephosphorylation and
inefficient cellular uptake due to their charged nature leading to further research aimed towards
improving them [57]. ProTides, a novel technology first employed by McGuigan [58], aims to mask the
phosphoryl oxygen groups in order to mask their charge and improve cellular uptake. This strategy
has proved successful in delivering drugs to the market such as sofosvubir and tenofovir alafenamide.
INX-08189, also known as INX-189, is a potent hepatitis C (HCV) virus replication inhibitor
prodrug prepared initially from a guanosine derivative (18 in Figure 10). The starting compound
undergoes masking and modification of the ester and amino acid moieties, as well as phosphorylation,
which allows the drug to become active intracellularly. Afterwards, the prodrug is prepared by
masking the phosphoryl group. INX-08189 (19 in Figure 10) was found to be 500 times more potent
than the parent nucleoside. Unfortunately, INX-08189 was discontinued in 2012 during phase II
development due to its high cardiac toxicity [59–61].
Structurally similar to INX-08189, both PSI-353661 (20 in Figure 10) and PSI-7977 have proceeded
to clinical evaluation with impressive early results. PSI-353661, a protide prodrug, was discovered by
Chang et al. in 2011 [62] and showed superior anti-HCV potency vs. the original guanosine derivative
Molecules 2017, 22, 1736 8 of 18
in addition to good stability (half-life > 24 h). PSI-7977 would later be acquired by Gilead Sciences
under GS-7977 and eventually marketed as Sovaldi®.Molecules 2017, 22, 1736 8 of 17 
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Figure 10. Chemical structure of guanosine derivative 18 and the prodrugs INX-08189 (19) and
PSI-353661 (20).
Sofosbuvir (21 in Figure 11, formerly GS-7977), on the other hand, is a protide analogue which
inhibits HCV NS5B polymerase and is now marketed under Sovaldi® following successful clinical trials:
PROTON, ELECTRON, QUANTUM, and ATOMIC [63]. Sofosbuvir is readily taken up by human
hepatocytes and undergoes a series of metabolic steps both enzymatic and non-enzymatic. The final
product is the triphosphate active form (see 22 in Figure 11) [64]. Though not a prodrug, ledipasvir
(GS-5855) a potent direct inhibitor of HCV NS5A [65], was the product of work by Link et al. [66] done
on a series of novel derivatives with benzimidazole-difluorene-imidazole cores. Following its success
in clinical trials [67], it is now combined in a single oral tablet with sofosbuvir marketed under the
name Harvoni® by Gilead Sciences (Foster City, CA, USA).
GS-6620 (23 in Figure 12), a C-nucleoside HCV inhibitor, was discovered by Cho et al. [68].
Named C-nucleoside for containing a 2′-C-methyl branched sugar it inhibits NS5B by preventing
nucleoside-triphosphates from binding to the active site [69]. While this drug exhibited potency
in phase I trials, it is hindered by intra- and inter-patient variability. Very recently, GS-5734 (24 in
Figure 12), has been discovered by Siegel et al. [70] for the treatment of Ebola virus (EBOV). The authors
report pre-clinical efficacy in nonhuman primate EBOV challenge model (EC50 = 86 nM) with a Phase
II study (PREVAIL IV) currently enrolling.
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Discovered in 2005 by Lee et al. [71], tenofovir alafenamide (GS-7340) (25 in Figure 13), has been
awarded FDA approval under the name Vemlidy® for the treatment of hepatitis B. The prodrug is
active orally and circulates in the plasma inactivated allowing for better distribution of tenofovir to
tissues [72]. Also, it was found to be safe and well tolerated in a series of trials [73–75].
Also, CMX157 (26 in Figure 13) a hexadecyloxypropyl conjugate of the acyclic nucleotide analogue
of tenofovir (27 in Figure 13). In phase I trials, the conjugate was found to have HIV hepatic targeting
and was 267-fold more active than tenofovir against HIV-1 and 300 fold more active than tenofovir
against multiple viruses in several different cell systems. Moreover, it was found to have wide
activity against all major subtypes of HIV-1 and HIV-2 in fresh human peripheral blood mononuclear
cells. Also, it was associated with higher intracellular levels of tenofovir–diphosphate conjugate than
observed with tenofovir. The authors report that the increased antiviral activity can be attributed to
increased cellular uptake and conversion to active diphosphate intracellularly. Moreover, a noticeable
increase in CMX157’s selectivity index was reported due to decreased EC50 values in MT-2 cells and
peripheral blood mononuclear cells (PMBCs) [61,76].
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6. Non-Nucleoside Antiviral Agents
In addition to synthesizing nucleoside prodrugs to overcome the drawbacks mentioned above,
another approach to designing novel antiviral agents is antiviral agents which are not based on
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nucleosides at all. This strategy aims to overcome the antiviral resistance towards nucleoside-based
antiviral agents as well as provide more potent and pharmacokinetically attractive agents.
Guo et al. [77] continue their previous experimentation with khellactone derivatives, such as
3′,4′-di-O-(S)-camphanoyl-(+)-cis-khellactone (DCK) (28 in Figure 14), [78] which has previously been
identified as a potent anti-HIV agent acting through the inhibition of HIV-1 double-DNA strand
formation [79,80]. The team investigated a series of camphanoyl-cis-kellactone molecules. Of the
13 synthesized and studied compounds ([3′,4′-Di-O-(S)-camphanoyl-4-methyl-(+)-cis-kellactone-3-yl]
methyl 2-aminopropanoate) (29 in Figure 14) showed the most promise in that it had the best
pharmacokinetic profile and enhanced oral bioavailability when compared to the parent compound.
The team believes that the molecule could be a potential anti-AIDS drug candidate.
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In a study by Schade et al. [83], a series of neuroaminidase inhibitor (NAI) prodrugs was synthesized 
with the structures of zanamivir and oseltamivir (32 and 33 in Figure 16, respectively) in mind. The 
authors’ strategy was to improve the pharmacokinetics profile of zanamivir by decreasing its basicity 
and to overcome the emerging resistance to oseltamivir while maintaining its oral bioavailability. 
Taking inspiration from the potent 5-guanidino substituted oseltamivir, the team used N-
hydroxylation and masking of polar groups as well as experimentation with N-hydroxyguanidine 
esters to identify potential prodrugs. Disappointingly, and keeping in mind the attractiveness of the 
strategies used by the authors, no convincing oral bioavailability was obtained, and hence, the 
bioavailability problems from which common NAIs suffer cannot be simply overcome by decreasing 
their basicity and solubility. 
Figure 14. Chemical structures of 3′,4′-di-O-(S)-camphanoyl-(+)-cis-khellactone (DCK) (28) and
[3′,4′-Di-O-(S)-camphanoyl-4-methyl-(+)-cis-kellactone-3-yl]methyl 2-aminopropanoate (29).
Regueiro-Ren et al. [81] have synthesized a series of HIV-1 attachment inhibitors derived from
4-fluoro-6-aza-indole analogues for clinical trials. The most promising candidate was fostemsavir
(BMS-663068) (30 in Figure 15), a prodrug of temsavir (31 in Figure 15), which has reached phase III
clinical trials [82]. The drug exhibits its HIV entry inhibitory action by blocking gp-120 HIV receptors
hence preventing attachment.
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bioavailability. Taking inspiration from the potent 5-guanidino substituted oseltamivir, the team used
N-hydroxylation and masking of polar groups as well as experimentation with N-hydroxyguanidine
esters to identify potential prodrugs. Disappointingly, and keeping in mind the attractiveness of
the strategies used by the authors, no convincing oral bioavailability was obtained, and hence, the
bioavailability problems from which common NAIs suffer cannot be simply overcome by decreasing
their basicity and solubility.Molecules 2017, 22, 1736 12 of 17 
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7. Nanoparticles
The modern approach to using nanoparticles as platforms for delivery of pharmaceutically active
compounds is being widely studied. Literature on the use of nanoparticles as antivirals, such as gold
and silver nanoparticles, has previously been reported [84–87]. Though, by loading active antivirals
onto nanoparticles, researchers aim to achieve better pharmacokinetics as well as targeted delivery.
In a study by Russo et al. [88] foscarnet/chitosan nanoparticles were prepared. Foscarnet marketed
under Foscavir® is the trisodium salt of phosphonoformic acid. While it inhibits of herpesvirus DNA
polymerase, drug- resistant cytomegalovirus (CMV) and HIV, it suffers from poor bioavailability and
is administered intravenously. Through foscarnet induced gelation of chitosan, the resulting initial
nanoparticle size was 200–300 nm increasing to 500–600 nm after being stable for 5 h in phosphate
buffer saline. The authors report that due to mucoadhesion of chitosan to mucosal epithelium this
delivery system could be effective for both oral and topical administration.
Cavalli et al. [89] report the use of β-cyclodextrin-poly(4-acryloylmorpholine) monoconjugate
(β-CD-PACM) to formulate nanoparticles to deliver acyclovir. The resulting acyclovir-loaded
nanoparticles were spherical and 200 nm in diameter. To measure the cellular accumulation of
acyclovir, the authors tested for acyclovir concentrations in Vero cells and report superior delivery
than the parent drug. Moreover, acyclovir-β-CD-PACM nanoparticles demonstrated higher potency
than free acyclovir (IC50 0.05 vs. 0.16).
In a study by Kumar et al. [90], lactoferrin nanoparticles were synthesized to improve
pharmacokinetics of AZT. AZT was loaded into lactoferrin nanoparticles by sol-oil chemistry with the
aid of olive oil leading to the encapsulation of AZT. The nanoparticles were spherical with a diameter
of 50–60 nm and tested on rat. The authors report that the loaded nanoparticles show no organ related
toxicity in contrast to free AZT. Also, as intended, longer circulation times were achieved due to
increased half-life of the nanoparticles (3.07 in male rats/3.27 h in female rats vs. 1.75 in males/1.92 in
females for free AZT).
8. Conclusions
Anti-viral agents hold plenty of potential for i prove ent due to the fact that they suffer fro
several drawbacks; mainly poor pharmacokinetics and development of resistance. Hence, the scientific
community continually explores several strategies to overcome those drawbacks or synthesize more
potent and attractive agents.
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The strategies employed in the last years in anti-viral research can be categorized into simple
or complex prodrugs. Of all the strategies employed: ester, targeted delivery, macromolecular,
nucleoside and nucleotide analogues, non-nucleoside analogues, and nanoparticles, the most
promising are macromolecular prodrugs; these explore the potential for conjugation of previously
known drugs to natural, semi-synthetic, and synthetic macromolecules, and nucleoside analogues.
Those macromolecules not only allow for the enhanced delivery of the anti-viral agent, but also for the
macromolecule onto which the agent is attached to exert its own effect on the virus.
Among the successful macromolecules is chitosan (COS), which was found to be an efficient
macromolecular carrier for AZT allowing for sustained release of the drug. Poly-2-hydroxyethyl
methacrylate (HPMA) and poly(methacrylic acid) (PMAA) were also shown to be successful
AZT carriers.
On the other hand, dendrimers have proven to be a very successful delivery system where the
dendrimers VivaGel® is now undergoing clinical trials. VivaGel works by two mechanisms: envelope
mediated and receptor mediated disruption. Nucleotide analogues witnessed productive years in the
recent past. Among successful examples of nucleotide analogues are sofosbuvir (formerly GS-7977),
a nucleotide analogue which inhibits HCV NS5B polymerase and is now marketed under Sovaldi®
following successful clinical trials: PROTON, ELECTRON, QUANTUM, and ATOMI, and tenofovir
alafenamide (GS-7340) which has been awarded FDA approval under the name Vemlidy® for the
treatment of hepatitis B. It can be said that the era of non-interferon based treatment of hepatitis
(through direct inhibitors of NS5A) has dawned: Harvoni® and Sovaldi® are such examples.
Additionally, nanoparticles have been used to improve the pharmacokinetic properties of
a number of antiviral agents: mucoadhesion of chitosan delivery system (foscarnet/chitosan
nanoparticles) was found to be effective in the treatment of herpesvirus DNA polymeraseand HIV
for both oral and topical administration. Further, acyclovir-β-CD-PACM nanoparticles demonstrated
higher potency than free acyclovir (IC50 0.05 vs. 0.16) to treat herpes simplex.
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